I take this to mean no side effects and patient has tolerated the initial treatment, being that phase 1 was efficacy etc. That is good as if palatability issues re raised its head then that would have been a significant backward step. This may also be why the faster movement to interim analysis.
Good on FightMND and PAA for getting the next cohort filled. Hopefully we see the 10c mark again.
Ann: MND Trial Completes Enrolment of Cohort 2, page-7
-
- There are more pages in this discussion • 98 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAA (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
18.0¢ |
Change
0.005(2.86%) |
Mkt cap ! $87.51M | |||
| Open | High | Low | Value | Volume |
| 17.5¢ | 18.3¢ | 17.5¢ | $205.5K | 1.150M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 55777 | 17.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 18.5¢ | 56756 | 2 |
View Market Depth
| Last trade - 16.10pm 06/08/2024 (20 minute delay) ? |
| PAA (ASX) Chart |